MAPT and Alzheimer disease: This study provides a biomimetic lipid nanocomposite (APLN/methylene blue) with high BBB penetration for AD therapy via a “Drug‐Carrier” synergy strategy, of which carrier for Aβ clearance and drug for inhibition of phosphorylated Tau.